Acadia Healthcare's Valuation Downgrade Signals Increased Financial Risk Ahead

Acadia Healthcare Co., Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. The company's valuation grade has shifted from fair to risky, reflecting a notable change in its financial metrics. Currently, Acadia Healthcare's P/E ratio stands at 8, while its Price to Book Value is recorded at 0.72. The EV to EBIT ratio is 9.27, and the EV to EBITDA ratio is 6.78, indicating the company's valuation relative to its earnings and cash flows. Additionally, the EV to Capital Employed ratio is at 0.83, and the EV to Sales ratio is 1.35. The company has reported a return on capital employed (ROCE) of 9.00% and a return on equity (ROE) of 8.80%. However, it has faced challenges, including a flat financial performance in the quarter ending September 2025 and a decline in net profit over the past nine months. The stock has also shown consistent underperformance against the S&P 500 over the last three years. For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.